Reviews/Dry Eye Disease Treatment/Rebamipide improves goblet cell density
Secretagogues · DED-SEC-02 · v2
Only three human studies in this corpus actually counted conjunctival goblet cells while testing rebamipide, and all three point the same way. In established dry eye, one small study showed the ocular surface becoming healthier at the cellular level [9], and another found goblet cell density improving on rebamipide much as it did on a comparator drug [3]. A cleaner randomised study in post-cataract-surgery patients showed rebamipide stopping the drop in goblet cells that surgery would otherwise cause [11]. But these studies are small, some are observational rather than randomised, one has no comparison group, and the surgical study is a different patient population. The large, well-designed rebamipide dry eye trials never measured goblet cell density at all [1][6][8][10], so a clear, measured increase in established dry eye has not yet been shown directly.
Three primary human studies measured goblet cells. [9], a single-arm study of fifteen patients over 12 weeks, reports significant improvement in squamous metaplasia grade (1.2 ± 0.1 to 0.3 ± 0.1, P = 0.004) and corneal epithelial cell density (660.1 ± 62.6 to 1015.5 ± 43.5 cells/mm2, P = 0.002), concluding improvement in ocular surface differentiation. [3], a retrospective observational study of 120 eyes, found goblet cell density among parameters that improved within-group but were comparable between rebamipide and diquafosol (P > 0.05). [11], a randomized trial after cataract surgery, found goblet cell density preserved with rebamipide (238.5 ± 116.6 before, 211.3 ± 184.4 cells/mm2 after, P = .55) while diclofenac alone caused a significant decline. The direction of effect is consistent across these independent designs. The contested point: The division is whether the corpus shows a measured increase in goblet cell density in established dry eye, or only indirect and off-target signals. The on-title study [9] reports squamous-metaplasia and epithelial-density figures rather than a stated goblet cell density value, [3] shows a within-group change not isolated from its comparator, and [11] shows prevention of surgical loss rather than an increase from a dry-eye-lowered baseline.
All 13 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The on-title paper [9] reports squamous metaplasia grade, corneal epithelial density and nucleocytoplasmic ratio but states NO explicit goblet cell density value, so citing it as direct evidence of increased density is inference from a proxy.
[9] is a single-arm uncontrolled study of N=15; any change is confounded by regression-to-mean and vehicle/placebo effects.
Where it remains uncertain. No large rebamipide dry eye RCT measured goblet cell density [1][6][8][10]; the on-title study [9] reports proxies rather than a stated density value, and [11] shows preservation after surgery rather than an increase in established dry eye.
Aleatory
The on-title study [9] enrolled only fifteen patients, so any measured change carries wide sampling variability.
Epistemic
The large rebamipide dry eye RCTs [1][6][8][10] never measured goblet cell density, leaving the question structurally unanswered at scale.
Inferential
Treating squamous-metaplasia reversal and ocular-surface differentiation in [9] as evidence of increased density is inference from a proxy.
The load-bearing papers from a corpus of 13, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Within-group improvement in DED signs under rebamipide; goblet cell density was among the assessed parameters.
“Changes from baseline were comparable between groups for OSDI, NItBUT, corneal and conjunctival staining score, meiboscore, meibum expressibility and quality, lipid thickness, impression cytology, and goblet cell density ( P > 0.05).”
Panel auditInternal validity: medium · scope of inference: Comparative effect of rebamipide vs diquafosol in short-tBUT DED over 3 months.Key limitations: retrospective nonrandomized · goblet cell density only reported as a drug-vs-drug comparison · no placebo arm
On-title study of rebamipide in DED; squamous metaplasia reversal is an inverse proxy for goblet cell recovery, but no explicit goblet cell density figure is reported.
“Topical use of 2% rebamipide for 3 months was associated with improvements in ocular surface differentiation due to changes of mucosal functions at the cellular level.”
Panel auditInternal validity: low · scope of inference: Cellular-level ocular surface changes under 2% rebamipide in definite DED over 3 months.Key limitations: no control arm · n=15 · goblet cell density measured but not reported · corneal epithelial density easily confused with goblet cell density
RCT evidence that concomitant rebamipide prevents the post-cataract-surgery decline in goblet cell density (preservation, not increase; surgical population).
“In Group B, the goblet cell density was not statistically different between before (238.5 ± 116.6 cells/mm2) and at 1 month after the surgery (211.3 ± 184.4 cells/mm2, P = .55).”
Panel auditInternal validity: medium · scope of inference: Whether concomitant rebamipide prevents NSAID/steroid-associated goblet cell loss after cataract surgery.Key limitations: post-cataract-surgery population, not DED · effect is prevention of loss, not increase above baseline · small per-group n
3 of 13 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The direction of effect is consistent across independent designs, but the directly on-claim evidence is too thin and indirect to exceed Uncertain.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No placebo-controlled density RCT in established dry eye. Every large rebamipide dry eye trial omitted goblet cell density, so the claim rests on small single-arm or observational data. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised, placebo-controlled dry eye trial with goblet cell density by impression cytology as a pre-specified endpoint.
Open question: Does 2% rebamipide produce a quantified increase in conjunctival goblet cell density versus placebo in established dry eye disease? Why it is still open: The large rebamipide dry eye RCTs [1][6][8][10] did not measure the endpoint, and [9] reports only proxies.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19